ImmunityBio, Inc.
ImmunityBio Settles Arbitration with Former Employees, Acquiring Key Intellectual Property and Drug Candidates
Summary
On July 13, 2024, ImmunityBio, Inc. finalized a Settlement Agreement and Release with Dr. Hing Wong and HCW Biologics, Inc., resolving all claims asserted in a consolidated arbitration. Under the Settlement, ImmunityBio acquired ownership of intellectual property, including issued patents, pending patent applications, and clinical drug candidates, potentially significant for its fusion protein platform in oncology. The acquired assets include molecules generated through a tissue factor-based fusion discovery platform related to the human transforming growth factor receptor (TGFb), with HCW9218, a heterodimeric fusion protein, having been studied in Phase 1/1b clinical trials for ovarian and pancreatic cancer. Additionally, ImmunityBio secured a worldwide, perpetual, irrevocable, royalty-free, exclusive license to exploit fusion proteins for several oncology targets.
Profitelligence Alerts
Get alerts for IBRX
Be first to know when ImmunityBio, Inc. files with the SEC.
Filing Categories
Advertisement
About ImmunityBio, Inc.
ImmunityBio, Inc. is a pioneering biotechnology company that focuses on developing innovative immunotherapies to treat cancer and other serious diseases. The company's primary function is to leverage the body's immune system to fight against various forms of cancer as well as infectious diseases through a robust pipeline of therapies. ImmunityBio's notable features include its expansive portfolio of next-generation therapies that incorporate cutting-edge technologies, such as the NANT Cancer Vaccine and Anktiva, which are designed to enhance the immune system's natural ability to identify and eradicate tumor cells. The company plays a critical role in the healthcare and biotechnology sectors, contributing to advancements in personalized medicine and potentially transformative treatments. Headquartered in California, ImmunityBio is strategically placed in the biotechnology hub of the United States, allowing it to effectively collaborate with key players in research and clinical development. Its work is significant in the market as it represents the ongoing shift towards immunotherapy as a front-line treatment for cancer, promising to impact patient outcomes and the future of cancer care.
Official SEC Documents
Advertisement